Background: The genetic risk of autoimmune hepatitis is insufficient to explain the observed risk, and epigenetic changes may explain disparities in disease occurrence in different populations within and between countries. The goal of this review was to examine how epigenetic changes induced by the environment or inherited as a phenotypic trait may affect autoimmune hepatitis and be amenable to therapeutic intervention. Materials and methods: Pertinent abstracts were identified in PubMed by multiple search terms. The number of abstracts reviewed was 1689, and the number of full-length articles reviewed exceeded 150. Results: Activation of pro-inflammatory genes in autoimmune disease is associated with hypomethylation of deoxyribonucleic acid and modification of histones within chromatin. Organ-specific microribonucleic acids can silence genes by marking messenger ribonucleic acids for degradation, and they can promote inflammatory activity or immunosuppression. High circulating levels of the microribonucleic acids 21 and 122 have been demonstrated in autoimmune hepatitis, and they may increase production of pro-inflammatory cytokines. Microribonucleic acids are also essential for maintaining regulatory T cells. Drugs, pollutants, infections, diet and ageing can induce inheritable epigenetic changes favouring autoimmunity. Reversal is feasible by manipulating enzymes, transcription factors, gene-silencing molecules and toxic exposures or by administering methyl donors and correcting vitamin D deficiency. Gene targets, site specificity, efficacy and consequences are uncertain. Conclusions: Potentially reversible epigenetic changes may affect the occurrence and outcome of autoimmune hepatitis, and investigations are warranted to determine the nature of these changes, key genomic targets, and feasible interventions and their consequences.
| INTRODUCTION
Autoimmune hepatitis is a complex immune-mediated liver disease of unknown cause [1] . A genetic predisposition has been described based mainly on the association of autoimmune hepatitis with certain human leucocyte antigens (HLAs) [2, 3] . These genetic associations have varied in different ethnicities and age groups. HLA DRB1*0301 and DRB1*0401 have been the principal genetic associations in White northern European and North American adults [4] [5] [6] . HLA DRB1*0404 and DRB1*0405 have been associated with the disease in Japan [7] [8] [9] [10] , mainland China [11] and Mexico [12] ; HLA DRB1*0405 and DQB1*0401 have distinguished patients in South Korea [13] ; and HLA DRB1*1301, DRB1*0405, DQB1*02 and DQB1*0603 have been implicated in South American patients by metaanalysis [14] . Furthermore, children in South America have had a different HLA phenotype (HLA DRB1*1301) than adults from the same region (HLA DRB1*0405) [15] , and North American [16] , South American [17] and European [18, 19] children with autoimmune hepatitis and antibodies to liver kidney microsome type 1 (anti-LKM1) have been distinguished by HLA DQB1*0201, DRB1*07 and DRB1*03.
The association of autoimmune hepatitis with diverse class II antigens of the major histocompatibility complex (MHC) suggests that genetic predisposition for the disease is based mainly on the selection and presentation of triggering peptides that vary in different countries, regions within countries and age groups [2, 3, 20, 21] . These peptides may reflect environmental exposures (pollutants, infectious agents and drugs) [21] or microbial products that translocate from the intestinal microbiome [22, 23] . Riskladen genetic loci outside the MHC are also being identified whose gene products may have pathogenic effects that influence the clinical phenotype of autoimmune hepatitis [3] . The rs3184504*A allele of the Src homology 2-B adaptor protein 3 gene (SH2B3) has been associated with the disease in northern European patients [24] , and its gene product may affect the coordination of signalling events that influence cell migration, inflammatory activity and T lymphocyte activation [25] . Like the loci within the MHC, the risk-laden loci outside the MHC lack disease specificity [26] and demonstrate variability between ethnic groups [24, 27, 28] .
Genomewide association studies (GWAS) and highdensity genotyping arrays promise to clarify the burden of genetic risk in autoimmune hepatitis [24, 29, 30] , but studies in other immune-mediated diseases have already suggested that genetic risk is unlikely to explain fully the observed risk for disease [31] . HLA DRB1*0301 and DRB1*0401 occur in only 51% and 55% of White North American patients with autoimmune hepatitis [5] , and the rs3184504 allele occurs in only 53% of northern European patients [24] . Other factors than genetic predisposition must be considered, and epigenetic changes that reflect environmental pressures may help explain ethnic, geographic and age-related variations in occurrence [32, 33] .
Epigenetic changes that influence the expression or function of genes without altering the sequence of deoxyribonucleic acid (DNA) have been implicated in the occurrence of diverse immune-mediated liver (nonalcoholic fatty liver disease [NAFLD] [34] and primary biliary cholangitis [PBC] [35] ) and nonliver (systemic lupus erythematosus [SLE] [36, 37] , rheumatoid arthritis [38] and systemic sclerosis [39, 40] ) diseases. These changes can account for the inheritance of stable phenotypic features [32, 33] , but they can also be altered and individualized by cues from the environment [41, 42] . Furthermore, they are amenable to therapeutic manipulation [32, 33, 43] .
Autoimmune hepatitis is just entering the era of epigenetic discovery as microribonucleic acids (miRNAs) are being identified that may influence the apoptosis and proliferation of activated T lymphocytes and serve as biomarkers of inflammatory activity [44] . The goals of this review are to describe the advances in epigenetics that help explain the occurrence of immune-mediated disease, indicate emerging opportunities for therapeutic intervention and encourage the investigation of this evolving science in autoimmune hepatitis.
tightness of the wrapping influences the accessibility of transcription factors to DNA binding sites and the activity of ribonucleic acid polymerase (RNAP) to open the double-stranded DNA and initiate the transcription of proteincoding and noncoding RNA [43, 48] . Tightly packed DNA within the nucleosomes constitutes heterochromatin, and it limits the binding of motifs that enhance gene activity. The key epigenetic mechanisms that modify chromatin structure and affect the accessibility of transcription factors to the DNA are DNA methylation [49, 50] and histone modification [51, 52] . The principal epigenetic factors that silence the translational activity of genes are the noncoding miRNAs [53] [54] [55] [56] [57] .
| DNA methylation
Deoxyribonucleic acid methylation typically occurs at cytosine nucleotides within regions of the DNA molecule in which the cytosine nucleotide is separated by a phosphate from a guanine nucleotide (CpG site) [32] (Figure 1 ). The CpG dinucleotides are in linear sequence along the DNA molecule, and the cytosines are methylated to form 5-methylcytosine by DNA methyltransferases using S-adenosylmethionine as the principal methyl donor [41, 58] . Methylation of the CpG sites represses gene activity by inhibiting the binding of transcription factors to DNA and by recruiting methyl-DNA binding domain proteins (MBDs) [32, 59] (Table 1) .
Methyl-DNA binding domain proteins are nuclear proteins that have a methyl-CpG-binding domain, and they bind specifically to methylated DNA [60, 61] . Different members of this family of proteins can have different effects on gene activity acting alone or in combination [62, 63] . They can suppress transcription when bound to methylated gene promoters, and they can recruit multiprotein complexes that contain diverse enzyme activities (histone deacetylases and histone methyltransferases) that can in turn alter chromatin structure and modulate transcriptional activity [63] [64] [65] [66] [67] [68] . MBDs may also have DNA demethylase activity [69, 70] . MBD2 promotes the oxidation of 5-T A B L E 1 Key epigenetic changes promoting autoimmunity Epigenetic Change Nature Consequences
DNA hypomethylation
Demethylated CpG dinucleotides in gene promoter region [32] Increased by TET enzymes [75] [76] [77] [78] Inhibited by DNMTs [33, 43, 70] Modulated by MBDs [60, 61, 71] Unpacks chromatin [33, 43] Promotes RNA polymerase activity [32] Increases gene transcription [33, 43] Associated with autoimmunity [41, 135] Histone modifications Phosphorylation, methylation, acetylation and ubiquitination of amino acids in histone tail [82] [83] [84] Histone acetyltransferase, histone deacetylase and PADs are key modifying enzymes [83, 84] BET proteins acetylate histones [235] Unpacks chromatin [32] Modulates transcriptional activity [52] Stimulatory and repressive effects [52] Acetylation tends to promote gene [85, 232] Deacetylation tends to repress gene [87, 88] Function and number of Tregs affected [91] Tends to promote autoimmunity [51, 93] MiRNAs Double-stranded [53] Length of 21-25 nucleotides [53] Mark mRNA for degradation [96] Organ-specific [100] [101] [102] [103] Subject to epigenetic changes [131] Gene-silencing effect [97, 98] Modulate DNMTs and cytokines [105] [106] [107] Maintain Tregs in mouse model [114] Associated with transplant tolerance [110] methylcytosine to 5-hydroxymethylcytosine [71] , and levels of MBD2 in T lymphocytes from patients with SLE have been directly associated with the degree of genomic hypomethylation [72] . Methyl-DNA binding domain proteins are essential for the activation of genes that modulate immune responses mediated by dendritic cells. In the absence of MBD2, dendritic cells have reduced activation and impaired ability to initiate an immune response, possibly because normally suppressed transcriptional repressors have been activated [73] . The impact of MBD binding on regulatory function is affected by the density of DNA methylation. Densely methylated regions typically have less regulatory activity, and MBD binding to these regions may have less impact than binding to hypomethylated active regulatory regions [65] .
Deoxyribonucleic acid methylation can be reversed by oxidation of the methylated CpG sites, and gene activity can be modulated by changes in the methylation status of the DNA [74] ( Table 1 ). The ten eleven translocation oxygenases (TET1-3) are an enzyme family that catalyses the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine, or 5-carboxylcytosine and this transformation can increase the transcriptional activity of the gene [75] [76] [77] [78] . DNA demethylation can also occur during early development or by excision repair of DNA patches in specific genes [74] . Gene promoters in autoimmune disease tend to be hypomethylated [41, 79] , but this finding has not been universal. The multidrug resistance 1 (MDR1) gene associated with refractory Crohn disease and ulcerative colitis is hypermethylated [80, 81] .
| Histone modification
Amino acids in the tail of the histone proteins can be modified by phosphorylation, methylation, acetylation and ubiquitination [82] [83] [84] (Figure 1 ). These post-translational modifications within the nucleosomes can influence the wrap of DNA and the transcriptional activity of the gene [32, 52] . The cumulative effects of alterations in multiple histone sites can modulate the cell phenotype, and this phenotype can change as various enzymes modify the histone code [32, 52] (Table 1 ). Histone acetyltransferase can transfer an acetyl group to an N-terminal lysine and increase gene activity [84] [85] [86] , and histone deacetylase can remove acetyl groups and repress gene activity [84, 87, 88] .
Histone acetylation typically characterizes activated genes, but the activated genes may have expressions that can promote or suppress disease activity [89, 90] . Histone acetylation can increase the number and suppressive function of regulatory T cells (Tregs) by preserving lysine acetylation of the FOXP3 transcription factor necessary for their development and activity [91] , but it can also increase the expression of pro-inflammatory genes [70] . Methylation of arginine residues by methyltransferases can promote gene activity, whereas conversion of histone methylarginine to citrulline by peptidylarginine deiminases (PADs) can repress gene activity [69, 83] .
Histone modifications have a less predictable effect on gene activity than the generally repressive effects of DNA methylation, and their effect can depend on the specific nature and location of the amino acid residues in the histone code. Transcriptional activity in cancer cell lines can be increased by methylation of lysine 27 of histone 3, and it can be decreased by methylation of lysine 4 in this same histone protein [33, 88, 92] . Histone modifications can also be erased by ligation with ubiquitin (ubiquitination) and commitment of the modified histone to proteasomal degradation [82] (Table 1) . Histone modifications tend to destabilize the genome, and they have been associated with the loss of self-tolerance in immune cells and the promotion of an autoimmune propensity [51, 93] .
| Noncoding microRNAs
Noncoding RNAs are regulatory molecules that influence gene expression without encoding a protein product, and miRNAs are a subgroup of this RNA family [32, 94] . MiRNAs are small double-stranded molecules ranging in length from 21 to 25 nucleotides that are generated inside the cell nucleus [53] . The initial transcripts are shortened by an endoribonuclease and exported to the cytosol. In the cytosol, the double-stranded molecule is shortened further by another endoribonuclease, and one strand acquires a sequence that can pair with messenger RNA (mRNA) [95] . Pairing of the miRNA with the mRNA marks the mRNA for degradation by a RNA-induced silencing complex (RISC) [33, 96] (Figure 1) . The binding of miRNA with mRNA may also repress the activity of protein-encoding genes without degrading the mRNA. This gene-silencing effect can occur if the nucleotide sequences between the miRNA and the mRNA are not perfectly complementary [53, 54, [97] [98] [99] .
MiRNAs have organ specificity, and they are critical for modulating the immune responses [100] [101] [102] [103] . They can affect multiple genes within an organ (multiplicity), and multiple miRNAs can target a single gene (cooperativity) [104] . MiRNAs can target mRNAs that regulate production of the DNA methyltransferases, and failures in enzyme production can limit DNA methylation and alter gene activity [105] . Cytokine pathways that direct the differentiation and proliferation of lymphocytes are regulated in part by the miRNAs [106, 107] and homeostatic mechanisms that suppress immune reactivity and tumour formation may also be affected by these gene-silencing molecules [108] [109] [110] ( Table 1 ).
The immunosuppressive activity of regulatory T cells (Tregs) is dependent on the transcription factor, foxhead box P3 (FOXP3) [111] , and demethylation of the FOXP3 gene in CD4 + T lymphocytes is associated with organ tolerance after kidney [112] and liver transplantation [110] . MiRNAs (miR-24, miR-31, miR-95, miR-146a and miR-155) are increased in the peripheral blood of patients tolerant of their transplanted liver [110] , and miR-155 has been required to maintain levels of Tregs in genetically modified mice [113] . The epigenetic effect of miRNAs on the number and function of Tregs may relate to reduced DNA methyltransferase activity and increased demethylation of FOXP3 [114] . MiRNAs modulate gene activities pivotal in hepatic metabolism and defence (Table 1) . MiR-122 is the most abundant miRNA in the liver, and it has gene suppressor activity in human hepatocytes [115, 116] . MiR-122 modulates hepatic production of cholesterol and lipoproteins [117] [118] [119] . Plasma levels of miR-122 have also correlated with serum aminotransferase levels in patients with liver disease [44, 120] , and the level of miR-122 in graft perseveration fluid has been associated with early graft loss after liver transplantation [121] . These findings have supported the consideration of miR-122 as a biomarker of liver injury [44, 120] . Both miR-21 and miR-122 have been increased in the circulation of patients with autoimmune hepatitis [44] .
Other miRNAs that have had an emerging epigenetic influence on maintaining hepatic homeostasis have been miR-191 and miR-222 (Table 1) . MiR-191 can affect the gene products that catalyse the demethylation of DNA (TET enzymes) [122] and that suppress tumour formation (p53 tumour suppressor protein) [123] . DNA hypermethylation has been associated with the occurrence of cholangiocarcinoma [124] , and deficiencies in the activities of the TET enzyme family may contribute to DNA demethylation and the invasive potential of this neoplasm [125] . MiR-191 suppresses the production of TET1 and impairs demethylation and activity of the p53 suppressor gene [126] . MiR-222 modulates hepatic fibrosis in a murine model of biliary atresia [102] , and it is upregulated in patients with cholangiocarcinoma [103] . MiR-222 may emerge as a biomarker for inflammatory injury and malignancy of the biliary tract [103] .
Over 1400 miRNAs have been described in humans [127] [128] [129] , and the multiplicity of their gene-silencing actions and consequences have not been fully incorporated into confident pathogenic pathways [100, 130] . Furthermore, the genes expressing the miRNAs are also subject to epigenetic mechanisms that affect their methylation status and activity [131, 132] . MiRNAs have a broad range of epigenetic effects, and their multiplicity and plasticity can complicate efforts at therapeutic manipulation.
| Epigenetic changes and autoimmunity
The epigenetic mechanisms of DNA methylation, histone modification and gene silencing by noncoding miRNAs can disrupt immune homeostasis and promote autoimmunity [33, 84, [133] [134] [135] [136] (Figure 1 ). Pivotal to the loss of self-tolerance is the hypomethylation of genes within T lymphocytes that may be underexpressed or normally silent [36, 135, 137] . The activity of CD4 + and CD8 + T cells is modulated in part by DNA methylation [133] , and the methylation status can change as the cells are activated [138] . Methylated CD8 + T cells with antigen memory undergo rapid demethylation after antigen stimulation [139] , and the hypomethylation of T lymphocytes in SLE upregulates the expression of killer cell immunoglobulin-like receptors (KIRs) on natural killer (NK) cells [140] and increases the production of interferon-gamma (IFN-c) and pro-inflammatory cytokines [141] . Demethylation of the Treg-specific demethylated region (TSDR) of the FOXP3 gene is required for stable expression of FOXP3 in Tregs and preservation of immunosuppressive function [142, 143] . Imbalances in the activities of the enzymes that methylate (DNA methyltransferases) and demethylate (TET1-3 family) DNA can shape the autoreactive response [135, 143] . Post-translational modifications (PTMs) of constituent proteins can also promote autoimmunity [69, 144, 145] . The PTMs can enhance the affinity of the modified self-proteins for presentation by class II MHC molecules, increase their recognition by T cell antigen receptors or create neo-epitopes that promote immune reactivity [144, 145] . Neutrophil activation is a prime mechanism for inducing PTMs as neutrophils can externalize and alter nuclear components that may trigger an adaptive immune response [146] . The PAD4 enzyme is expressed in granulocytes, and PAD4 can induce deimination of histones (conversion of arginine to citrulline) in various protein substrates [147] . In rheumatoid arthritis, the post-translational modification of fibrin by PAD enzymes generates citrullinated autoantigens that can be correlated with the severity of synovial inflammation and radiographic manifestations of joint damage [148, 149] . Prevention or reversal of the PTMs is a feasible mechanism by which to modify autoantigens and decrease their immunogenicity [69, 147] . Inhibitors of PAD deiminase activity have been useful in the treatment of experimental collagen-induced arthritis [150] , colitis [151] , SLE [152] and multiple sclerosis (MS) [153] .
| Epigenetic changes and environmental cues
Environmental pressures can alter the epigenetic mechanisms that modulate gene activity and in turn affect the occurrence and phenotype of autoimmune disease [41, 84, 154] . These pressures may help explain the discordance of autoimmune diseases in monozygotic (MZ) twins [84, 155] and the variations in disease occurrence and phenotype in different age groups and countries [21, 154] . Epigenetic modifications cued by the environment may be the intermediate elements that bridge "nurture" and "nature."
| Epigenetic drift
Global and locus-specific differences in DNA methylation and histone acetylation have been found in MZ twins [79, 155] , and these epigenetic distinctions, which are absent during early stages of life, emerge during ageing ("epigenetic drift") [155] . Thirty-five per cent of twin pairs have different genomic content of 5-methylcytosine and histone acetylation, and the acquired epigenetic changes are associated with older age, less time spent together and medical history [155] . DNA methylation may increase or decrease during replication, and "epigenetic drift" may reflect the instability of the methylated state with ageing [156] [157] [158] . Alternatively, in genetically identical MZ twins of near equal age, the effects of environmental exposures unique to the individual must be considered [41] .
Monozygotic twins discordant for SLE have widespread differences in genomic DNA methylation, particularly in genes involved with immune reactivity [79] . Global reduction in 5-methylcytosine and DNA methylation has distinguished the affected twins, and the changes have been accompanied by reductions in the mRNA levels that direct the synthesis of DNA methyltransferases [79] . Similarly, differences in genomic DNA methylation have been described between ethnic groups within the United States, and these differences may contribute to natural variations in disease susceptibility [154] . Epigenetic changes can distinguish genetically identical and genetically dissimilar individuals, and these distinctions may accrue as environmental cues drive an "epigenetic drift" [135] .
| Environmental cues
The main environmental cues that have been associated with epigenetic modifications are drugs, pollutants (tobacco smoke, aerosolized particles, heavy metals, radiation and ultraviolet light), infections and diet (especially deficient sources of methyl donors and vitamin D) [32, 36, 41, 42, 159] (Table 2) . Ageing is a natural consequence that may also contribute by increasing the opportunity for toxic exposure [41] and by inducing genomic instabilities through repeated cycles of DNA replication [157, 158, 160] .
Procainamide, hydralazine, isoniazid, methyldopa, chlorpromazine, phenytoin and 5-azacytidine mainly induce DNA demethylation, and most have been associated with lupus-like reactions [161] [162] [163] (Table 2) . Procainamide inhibits DNA methyltransferase activity and prevents the transfer of methyl groups from S-sdenosylmethionine to DNA [164] . Hydralazine inhibits the extracellular signalregulated kinase (ERK) pathway that controls the expression of mRNA, and it impairs the synthesis of DNA methyltransferases 1 and 3a [165] . 5-Azacytidine is a chemical analogue of the nucleotide cytosine, and its incorporation into DNA inhibits DNA methylation by inactivating DNA methyltransferases [166] .
Tobacco smoke is one of the many pollutants that can induce epigenetic changes [41] (Table 2) . Tobacco smoke stimulates the deimination of proteins by converting arginine to citrulline, and citrullinated proteins have been associated with disease activity in rheumatoid arthritis [148, 149, 167] . Tobacco smoking has been associated with progressive hepatic fibrosis in PBC [168, 169] and the occurrence of SLE, MS and Graves' disease [170, 171] . Other pollutants include aerosolized particulate matter that has been associated with global and gene-specific reductions in DNA methylation in elderly inhabitants of Boston [172] and steel plant workers in Italy [173] . Heavy metals (arsenic, mercury, nickel, chromium and cadmium) induce mainly DNA hypermethylation and variable gene activity [174] , and the industrial solvent trichloroethylene promotes DNA hypermethylation and reduced transcriptional activity [175] .
Infectious agents, as exemplified by the Epstein-Barr virus, can also induce epigenetic modifications ( Table 2 ). The Epstein-Barr virus has hypomethylated regions within its genome [176] , and entry of the viral DNA into the cell nucleus can induce the production of virus-encoded transcription factors that activate genes affecting cell proliferation [177, 178] . Methylation of the CpG sites within the virus can silence the viral genes [179] Dietary supplementation with soy-derived isoflavones (genistein) increases methylation of DNA CpG sites and alters the coat colour of offspring when administered to female mice before mating and during pregnancy and lactation [180] (Table 2) . Similarly, dietary supplementation with methyl donor groups prevents transgenerational obesity in mice [159, 181] , and diets during pregnancy that have been enriched with high energy sources alter DNA methylation and induce an inheritable epigenetic mark in mice [182] . In contrast, dietary depletion of methyl donor groups in inbred mice results in hepatic steatosis that is accompanied by loss of cytosine methylation, aberrant histone modifications and altered expression of DNA methyltransferases [183] .
Environmental pressures can induce epigenetic changes that alter gene activity and promote disease occurrence [161] [162] [163] . They can induce PTMs in proteins that promote immunogenicity [148, 149, 167] , and they can induce a transgenerational epigenetic mark that can be demonstrated in the genome and phenotype of offspring [159, [180] [181] [182] . Environmental cues impart plasticity to the epigenome and can have transgenerational effects.
| Epigenetic changes in PBC, PSC and NAFLD
Studies are just beginning to explore the role of epigenetics in the pathogenesis of PBC, PSC and NAFLD. Early findings have implicated alterations in DNA methylation and certain miRNAs in disease occurrence [44, 128, 184] .
| PBC
The CXCR3 gene promoter in the X chromosome of CD4 + T lymphocytes is demethylated in patients with PBC, and the level of demethylation correlates inversely with the expression of CXCR3 [35] (Table 3 ). Significant differences in DNA methylation have also been found in multiple other gene promoters in the X chromosome of CD4 + , CD8
+ and CD14 + T lymphocytes [35] . CXCR3 is a pivotal cytokine receptor that orchestrates the migration of activated T lymphocytes and NK cells to sites of tissue injury [185, 186] , and its increased expression could influence the progression of PBC [35] . Furthermore, miR-451a and miR642a-3p have predominated over other aberrantly expressed miRNAs in exosomes isolated from the plasma of patients with PBC, and they may constitute epigenetic changes that affect the activity of immune regulatory genes [187] . In rheumatoid arthritis, miR-451 has been associated with increased cytokine levels and disease severity [188] .
| PSC
Twenty-one miRNAs are expressed differentially in PSC, and 33 miRNAs distinguish patients with cholangiocarcinoma with and without PSC from control subjects [103] ( Table 3 ). The principal serum marker of patients with PSC is miR-200c, and the main serum markers of patients with cholangiocarcinoma are miR-222 and miR-483-5p. MiR-200c is downregulated in patients with PSC compared to control subjects and upregulated in patients with cholangiocarcinoma compared to patients with PSC [103] . MiR-222 and miR-483-5p are both upregulated in patients with cholangiocarcinoma compared to patients with PSC [103] . The miRNAs reflect dysregulated gene expression, and they implicate epigenetic factors in the disease process, albeit their pathogenic contributions remain obscure.
T A B L E 2 Environmental cues associated with epigenetic modifications

Environmental Cues Agent(s) Epigenetic Changes
Drugs Procainamide, hydralazine, isoniazid, methyldopa, chlorpromazine, phenytoin, 5-azacytidine [161] [162] [163] Mainly DNA demethylation [161] [162] [163] . Procainamide inhibits DNMTs [164] . Hydralazine limits mRNA for DNMTs [165] . 5-azacytidine blocks DNA methylation [166] . Most induce lupus-like reactions [161] [162] [163] .
Pollutants Tobacco smoke [41] Aerosolized particles [172, 173] Tobacco smoke induces deimination [41] Aerosolized matter induces demethylation [172] Heavy metals Arsenic, mercury, nickel, chromium, cadmium [41, 174] Mainly DNA hypermethylation [174] Variable transcriptional activity [174] Toxins Trichloroethylene [41, 175] DNA hypermethylation [175] Reduced transcriptional activity [175] Infections Epstein-Barr virus [41, 176] Hypomethylated virus genome [176] Virus-encoded transcription factors [177, 178] Activates genes for cell proliferation [177, 178] Diet Isoflavones (pregnancy) [180] Methyl groups (pregnancy) [181] High energy diets (pregnancy) [182] Vitamin D deficiency [198] Genistein induces DNA hypermethylation [180] Methyl donors prevent heritable obesity [159] High energy diet alters DNA methylation [182] Vitamin D deficiency increases immune and fibrotic responses [201] Supplements S-adenosylmethionine [70, 249] Reduces demethylase activity [249] Inhibits MBD2 activity [249] DNA, deoxyribonucleic acid; DNMTs, deoxyribonucleic acid methyltransferases; MBD2, methyl-DNA-binding domain protein 2; mRNA, messenger ribonucleic acid. Numbers in brackets are references.
Aberrant DNA methylation has also been described in several genes associated with cholangiocarcinoma, including cancer lines from patients with cholangiocarcinoma and PSC [189] [190] [191] . These insights may clarify mechanisms of malignant transformation in PSC and identify biomarkers that reflect a predisposition for biliary cancer [190] .
| NAFLD
Nine genes have shown differential DNA methylation (increased or decreased methylated CpG sites) and expression of mRNAs in liver tissue from obese patients with NAFLD [192] (Table 3 ). The implicated gene products have included an enzyme that catalyses the metabolism of glucose and lipids (adenosine triphosphate [ATP] citrate lyase) and a protein that mediates insulin signalling (insulin-like growth factor binding protein 2) [192] . Liver samples obtained 5-9 months after bariatric surgery have indicated reversal of the changes [192] . Diet-induced weight loss in overweight or obese men has also been associated with increased methylation of several CpG sites of specific genes of uncertain function [193] . The findings suggest that epigenetic changes may contribute to obesity and insulin insensitivity and be reversible by weight reduction strategies.
Forty-six miRNAs have been differentially expressed in liver tissue from patients with nonalcoholic steatohepatitis (NASH), including 23 that have been upregulated and 23 that have been downregulated [104, 128] (Table 3) . MiR34a and miR-146b have been the principal upregulated miRNAs, and miR-122 has been the main downregulated molecule. In NASH, miR-122 has more than 40 gene targets that can affect cell growth, cell differentiation, apoptosis, inflammation and metabolism, including the expression of several lipogenic enzymes [104] . Epigenetic biomarkers may evolve as monitors of disease behaviour and treatment response and as targets for therapeutic manipulation.
| Epigenetic changes in autoimmune hepatitis
Autoimmune hepatitis has lagged behind PBC, PSC and NAFLD in exploring epigenetic bases for its variable occurrence and manifestations. Circulating levels of miR- MiR-451a and miR-642a-3p increased [187] Demethylation correlates inversely with CXCR3 expression [35] CXCR3 orchestrates immune and NK cell migration to injury site [185, 186] MiRNAs affect immune regulation [187] PBC progression may result [35] PSC 21 miRNAs distinguish PSC [103] 33 miRNAs distinguish CAC [103] MiR-200c principal marker of PSC [103] MiR-222, 483-5p upregulated in CAC [103] Aberrant methylation of CAC genes [191] Uncertain pathogenic effects [103] Possible biomarkers for PSC, CAC [190] NAFLD Differential methylation of 9 genes [192] Disrupted insulin signalling and metabolism [192] 46 miRNAs differentiated in NASH [104, 128] MiR-34a and miR-146b upregulated [104, 128] Downregulated miR-122 affects lipids [104] Bariatric surgery reverses some changes [192] Weight loss increases gene methylation [193] Metabolic pathways altered by gene methylation and miRNAs [104, 192] Weight reduction may reverse some epigenetic changes [192, 193] AIH MiR-21 increased in Japanese patients [44] MiR-21 and miR-122 correlate with ALT [44] Low miR-21 and miR-122 in cirrhosis [44] MiR-21 targets PDCD4 gene [44, 194] MiR-122 increases INF-1 production [196] Vitamin D deficiency alters VDRE effects on gene activity [215, 216] MiR-21 and miR-122 are possible biomarkers of inflammatory activity [44] MiR-21 and miR-122 have proinflammatory effects [194] [195] [196] Dysregulated immune and fibrotic responses [201] AIH, autoimmune hepatitis; ALT, serum alanine aminotransferase level; CAC, cholangiocarcinoma; CXCR3, chemokine designation indicating sequence of cysteine (C), variable amino acid (X), cysteine (C) receptor (R) 3; DNA, deoxyribonucleic acid; INF-1, interferon type 1; miR, microribonucleic acid subtype; miRNAs, microribonucleic acids; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NK, natural killer; PBC, primary biliary cholangitis; PDCD4, programmed cell death 4 gene; PSC, primary sclerosing cholangitis; VDRE, vitamin D response element. Numbers in brackets are references.
21 have been differentially elevated in Japanese patients with autoimmune hepatitis, and serum levels of miR-21 and miR-122 have reflected serum alanine aminotransferase levels [44] (Table 3) . Furthermore, the miR-21 level has correlated directly with the histological grade of inflammation and inversely with the histological stage of fibrosis [44] . The significant reduction in the serum miR-21 and miR-122 levels in patients with cirrhosis has suggested that both miRNAs are biomarkers of inflammatory activity.
| MiR-21 and miR-122 as biomarkers of inflammatory activity
MiR-21 is expressed in T lymphocytes, and it targets a variety of genes, including the programmed cell death 4 (PDCD4) gene, that affect cellular proliferation, migration and apoptosis [44, 194] . Downregulation of PDCD4 by miR-21 can decrease the apoptosis of activated T lymphocytes, increase the secretion of pro-inflammatory cytokines (tumour necrosis factor-alpha and interferon-gamma) and promote inflammatory activity [195] . In contrast, miR-122 is liver-specific [130] , and it can increase the production of interferon type 1 by blocking a suppressor of cytokine signalling [196] . Both miRNAs are pro-inflammatory but by different putative pathways, and they lack disease specificity. Comprehensive DNA methylation studies have not been performed in autoimmune hepatitis. Such assessments are needed to complement an extension of microarray analyses that continue to detail the differentially expressed miRNAs.
| Serum vitamin D level as biomarker of epigenetic changes
Low circulating levels of 25-hydroxy-vitamin D have been described in most patients with noncholestatic chronic liver diseases, including autoimmune hepatitis [197] [198] [199] [200] [201] [202] . Vitamin D3 is the natural skin-derived form of vitamin D, and it is hydroxylated in the liver to 25-hydroxy-vitamin D [203] . This hydroxylated form is metabolically inactive, and it is converted to the active metabolite of 1, 25-dihydroxyvitamin D in the kidney [203] . Vitamin D deficiency in chronic liver disease most likely reflects progressive hepatic fibrosis and impaired vitamin D3 hydroxylation [197, 198, 200] , but reduced exposure to sunlight, malabsorption, dietary deficiency, and drug effects on vitamin D metabolism may also contribute [198, 204] . Diverse immune regulatory and antifibrotic effects have been ascribed to 1, 25-dihydroxyvitamin D [201] , and the serum 25-hydroxy-vitamin D level may be a biomarker of epigenetic modifications in autoimmune hepatitis [202] . The immune regulatory effects of 1, 25-dihydroxyvitamin D include modulation of nuclear DNA polymerase and protein kinase activity affecting cell proliferation [205, 206] , regulation of FOXP3 expression in CD4 + T cells by activating the FOXP3 gene [207, 208] , stimulation of cytotoxic T lymphocyte antigen-4 (CTLA-4) and IL-10 production in experimental colitis [209] and downregulation of intracellular expression of Toll-like receptors in human monocytes [210] . The antifibrotic effects include inhibition of hepatic stellate cell activation by suppressing profibrotic SMAD3 genes [211, 212] , stimulation of matrix metalloproteinases [213] and reduction in collagen deposition by myofibroblasts [213, 214] . The epigenetic changes induced by 1, 25-dihydroxyvitamin D are probably dependent on the ligation of this active metabolite with the vitamin D receptor (VDR). The ligation in turn regulates gene expression by binding to the vitamin D response element (VDRE) in genes [215] . This interaction recruits enzymes and co-activators that can induce histone acetylation and structural changes in chromatin that enhance gene transcription [216] . Vitamin D upregulates the mitogen-activated protein kinase phosphatase-1 (MKP-1) pathway, reduces p38 activation in human monocytes and macrophages and inhibits the production of pro-inflammatory cytokines [217] [218] [219] . Inhibition of the p38 mitogen-activated protein kinase (MAPK) pathway has improved experimental autoimmune hepatitis [220] , and vitamin D deficiency may constitute an epigenetic pathway that is acquired by progression of the liver disease or by deficiencies in the environment.
| Epigenetic changes and therapeutic opportunities
The epigenetic changes that promote the overexpression of pro-inflammatory genes and the underexpression of immunosuppressive genes are logical therapeutic targets in immune-mediated disease, and they warrant assessment in autoimmune hepatitis [32, 43] .
| Preferred targets
The successful targeting of a disease-associated epigenetic mark requires awareness of the gene activities that will be affected, knowledge of the enzymatic isotypes that affect the aberrant gene expression, molecular agents that can reverse the chosen mark, and precision in altering the desired site [70] (Table 4) . Genomewide association studies can identify the genes associated with the disease and regions in the genome that are enriched with multiple gene enhancers [43] . Regulatory genes and their protein products are key players in modifying the immune response, and epigenetic changes in the sites that affect their expression are preferred targets. Most causal variants described in diverse autoimmune diseases map to enhancer regions, and they tend to occur near binding sites for regulators of gene activation and immune cell differentiation [221] . Superenhancers are regions in the genome in which multiple enhancers are collectively arrayed near genes that regulate cell identity. The super-enhancers are prime sites to target for epigenetic modification because they are usually near genes that are highly expressed [222] [223] [224] .
| Key elements
The key elements that can be manipulated to remodel the chromatin structure or silence pro-inflammatory genes in autoimmune disease are the enzymes that affect DNA methylation and histone modification, the miRNAs that mark pro-inflammatory mRNAs for degradation, and the binding proteins that can alter chromatin structure and gene performance ( Table 4 ). The methylation state of CD4 + lymphocytes is maintained by DNA methyltransferases [59, 225] , and it is reduced by the TET enzyme family [75] [76] [77] [78] . Histone modifications are influenced by enzymes including the histone deacetylases (HDCAs), histone acetyltransferases (HATs), histone methyltransferases (HMTs), histone demethylases and the PAD enzyme family [69, 83, [85] [86] [87] [88] . MiRNAs can be manipulated by antisense oligonucleotides that inactivate mRNA before translation to miRNAs [226, 227] and by epigenetic modifications of methylation-sensitive genes that express the miRNAs [109, 110, 131, 132] . All elements have been manipulated in experimental models of immune-mediated and malignant diseases [33, 43, 70, 126, 228, 229] .
T A B L E 4 Therapeutic considerations for inducing epigenetic modifications
Considerations
Nature Desired Consequences
Key gene sites Enhancer regions in regulatory genes [221] Super-enhancer regions where multiple enhancers arrayed near highly expressed genes [222] [223] [224] Silence pro-inflammatory genes [70] De-repress anti-inflammatory genes [70] Feasible molecular targets
DNA demethylation
• increases transcriptional activity [32] • reduced by methyltransferases [59, 225] • increased by TET enzymes [75] [76] [77] [78] Histone modifications
• tend to increase transcription [85, 232] • altered by HDCAs, HATs, HMTs, histone demethylases, PADs [69, 83, 86] Disease-specific miRNAs
• silence anti-inflammatory genes [97, 98] MBDs
• increase gene demethylation [71] BET proteins
• increase histone acetylation and transcriptional gene activity [43, 232] Tighten DNA wrapping of nucleosomes [43] Reduce binding of transcription factors [43] Limit RNA polymerase activity [32, 48] Silence pro-inflammatory genes [70] De-repress anti-inflammatory genes [70] Improve Tregs number and function [142, 143] Reduce autoreactive T cell activity [135, 137] Main prospects Inhibitors of MBDs [70, 231] Inhibitors of histone acetyltransferases [70] BET inhibitors [43, 232] Evidence-based lifestyle changes [32] Methyl donor supplements [249] Vitamin D supplements [198, 202] Prevent DNA demethylation in T cells and increased transcriptional activity [70] Reduce histone acetylation and silence proinflammatory genes [70, 247] Prevent histone acetylation [232] Reduce pro-inflammatory cytokines [217, 220] Interventional caveats
Lack of target specificity [70] Unsuspected unwanted consequences [70] Possible deleterious inheritable trait [32, 45] Characterization of aberrant gene activity [70] Clarification of enzyme isotypes activating aberrant gene expression [70] Interventions targeting specific isotype [70] Full delineation of associated risks [32, 70] BET, bromodomain and extra-terminal (BET) proteins; DNA, deoxyribonucleic acid; HATs, histone acetyltransferases; HDCAs, histone deacetylases; HMTs, histone methyltransferases; MBDs, methyl-DNA binding domain proteins; miRNAs, microribonucleic acids; PADs, peptidylarginine deiminases; RNA, ribonucleic acid; TET, ten eleven translocation oxygenases; Tregs, regulatory T cells. Numbers in brackets are references.
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The key proteins that can be considered for manipulation are the MBDs and the bromodomain and extra-terminal (BET) family (Table 4) . MBDs can remodel the nucleosome, induce histone deacetylase activity and strengthen gene silencing [64, 66, 230] . They may also derepress dendritic cell activity and enhance immune responsiveness [73] or act as a demethylase to activate transcription [60, [69] [70] [71] . MBD2 in T lymphocytes from patients with SLE has correlated with DNA hypomethylation and increased transcriptional activity [72] , and inhibitors of MBD2 have been proposed as molecular interventions in autoimmune disease [70] . Antisense oligonucleotides have inhibited MBD2 and decreased tumorigenesis in human cancer cell lines [231] .
The bromodomain-containing proteins bind acetylated lysine residues in the histone proteins, and they attract other elements that modify the histones and promote transcriptional activity [232] . The BET family has histone acetyltransferase activity, and it can increase gene activity by acetylating lysine residues in the histone proteins [233] [234] [235] . Inhibitors of the BET proteins can block binding of the acetylated histone to the BET proteins and reduce transcriptional activity of the gene [232] .
Molecular inhibitors of the BET proteins have reduced the activity of super-enhancers and decreased disease-associated gene expression in T lymphocytes from patients with juvenile idiopathic arthritis (JIA) [236] . They have reduced the differentiation of na€ ıve CD4 + T cells into T helper (Th) 17 lymphocytes [237] , conferred protection against lipopolysaccharide-induced endotoxic shock [238] , downregulated the expression of pro-inflammatory gene products by na€ ıve CD4 + T cells [232] and inhibited antigen-specific T cells from inducing experimental autoimmune encephalomyelitis after adoptive transfer [232] .
| Site-specific targeting
Histone-modifying enzymes are sequence-specific, and they are active at particular genomic sites because of sequencespecific binding factors [70] . Similarly, DNA-modifying enzymes are directed to specific genomic sequences influenced by cell-specific patterns of DNA methylation [70, 239, 240] . Different isotypes of the same enzyme family can influence the expression of specific genes in certain cells depending on the genomic sequence and other binding proteins within the cell's microenvironment [70] . Molecular interventions are feasible that target the chromatin-modifying enzyme activity in certain cells and genomic sequences. Keys to the accurate targeting of these enzyme imbalances are characterization of the aberrant gene activity pivotal to the clinical phenotype of the disease, delineation of the specific enzyme isotypes contributing to the aberrant gene expression and availability of molecular interventions that target the isotype-specific enzyme or gene-specific miRNA [70] .
| Prospects
Epigenetic therapies have evolved mainly in the management of malignant diseases in which inhibitors of DNA methyltransferase activity [241] [242] [243] and histone deacetylase activity [244] have been used to promote the expression of tumour suppressor genes and upregulate the expression of tumour rejection antigens. MiRNA replacement therapy (miR-34) has also been evaluated as a mechanism by which to suppress human malignancy [32, 245] . These interventions have been designed to increase transcriptional activity of genes that inhibit the growth or viability of tumours. In autoimmune diseases, the regulatory genes are mainly hypomethylated or acetylated, transcriptional activity is increased, and miRNAs are abundant [33, 44, 84, 135, 246] . Interventions that reduce transcriptional activity of the pro-inflammatory genes or activate the antiinflammatory genes would be appropriate. These interventions remain largely theoretical, especially in autoimmune hepatitis.
Deoxyribonucleic acid hypomethylation can be reversed, but it has been difficult to achieve [33, 43] (Table 4 ). The MBDs that bind specifically to methylated DNA have been proposed as therapeutic targets [70] . MBD2 has been implicated in the demethylation of T cells and an increase in transcriptional activity in SLE [70] . MBDs have also silenced methylated genes in other models [63] [64] [65] [66] [67] [68] . These disparate actions of the MBDs require clear definition of the MBD subtype to be targeted in autoimmune hepatitis, and inhibition of MBD2 is a logical objective. Antisense oligonucleotides that inhibit MBD2 have decreased tumorigenesis in human cancer cell lines and in nude mice [231] . Molecular inhibitors of histone acetyltransferases are also in development, and they may emerge as interventions that silence pro-inflammatory genes by reducing the acetylation of histones [70, 247] .
Inhibitors of histone deacetylase activity have unpredictable effects in autoimmune disease [248] , and therapeutic modulation of miRNAs is still in its infancy [100, 130] . Molecular interventions that inhibit the binding of BET proteins to acetylated histones have silenced genes in animal models of autoimmune disease [232] and in cells derived from patients with JIA [236] (Table 4 ). They constitute another feasible therapeutic consideration in autoimmune hepatitis, albeit the findings in autoimmune disease are preliminary and BET inhibitors are unevaluated in models of autoimmune hepatitis.
The therapeutic epigenetic interventions still lack precision, disease specificity and proven safety. A major concern is that the manipulation of these complex and interactive mechanisms of gene activity will have unsuspected and unwanted consequences. Furthermore, the manipulated epigenetic change may become an inheritable trait that involves subsequent generations. The epigenetic alteration must have a highly specific and predominant beneficial effect directed at the principal aberrant gene expression contributing to the disease, and it must also have transgenerational tolerance.
| Near-future expectations
Global disparities in the occurrence and outcome of autoimmune hepatitis and the inability to attribute all disease risk to genetic factors are driving efforts to identify contributory environmental elements [21] . Populations at risk for autoimmune hepatitis may well be identified not only by their genetic predisposition but also by their exposure to environmental factors that induce risk-laden epigenetic changes. Vitamin D deficiency has been associated with advanced fibrotic liver disease [198, 200, 202] , and it is a correctable abnormality that should be assessed in all patients with chronic liver disease [198] . Evidence-based lifestyle modifications, including diet, may protect genetically predisposed individuals and prevent future generations from inheriting deleterious epigenetic traits [32] .
S-adenosylmethionine, the methyl donor involved in DNA methylation, has inhibited intracellular demethylase activity, including the demethylase activity of MBD2, in a dose-dependent manner in cell lines [249] . The methyl residue on S-adenosylmethionine is required for inhibition of demethylase activity, and the finding suggests that supplemental donation of methyl groups may prevent or reverse gene demethylation and silence aberrant gene expression. S-adenosylmethionine is an available dietary supplement, and its potential role in modifying aberrant gene activity in autoimmune hepatitis is another logical investigational tract.
Vitamin D supplementation can correct a deficiency state, and it has prevented fibrosis in experimental models of toxin-induced liver disease [250] . Supplementation has not reversed established cirrhosis in this model, but longterm studies have yet to be performed to assess sustained improvement in clinical indices and pathogenic pathways.
| Overview
Disease-associated epigenetic changes have been demonstrated in systemic autoimmune diseases and diverse liver diseases, including autoimmune hepatitis. Interventions that can modify these changes, reduce transcriptional activity of pro-inflammatory genes, and limit the production of gene products that disrupt homeostatic pathways are desirable and feasible. Common features of immune-mediated and inflammatory liver diseases have been hypomethylation of DNA, acetylation of histone proteins and increased plasma levels of miRNAs. Molecules that interrupt the demethylase activity of MBD2 or inhibit binding of BET proteins to acetylated histones are potential therapeutic interventions in autoimmune hepatitis. Antisense oligonucleotides that target liver-specific miRNAs that suppress anti-inflammatory and immunosuppressive gene activity are also considerations. Environmental precautions and supplemental dietary modifications enriched with methyl groups or 1, 25-dihydroxyvitamin D are ancillary measures that also warrant study. The epigenetic features associated with autoimmune hepatitis must be fully described to develop disease-relevant animal models, evaluate the applicability of evolving management options, and understand the immediate and long-term consequences of these manipulations. The science of epigenetics is expanding, and autoimmune hepatitis must be included within this domain [251] .
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